Miller Anestesia

96. Lien CA: The role of stereoisomerism in neuromus-

cular blocking drugs. Curr Opin Anesthesiol 9:348–

353, 1996.

97. Lien CA, Belmont MR, Abalos A, et al: The cardio-

vascular effects and histamine-releasing properties

of 51W89 in patients receiving nitrous oxide/

opioid/barbiturate

anesthesia. Anesthesiology

82:1131–1138, 1995.

98. Savarese JJ, Wastila WB: The future of the benzyli-

soquinolinium relaxants. Acta Anaesthesiol Scand

Suppl 106:91–93, 1995.

99. Lien CA, Schmith VD, Embree PB, et al: The phar-

macokinetics and pharmacodynamics of the stere-

oisomers of mivacurium in patients receiving

nitrous oxide/opioid/barbiturate anesthesia. Anes-

thesiology 80:1296–1302, 1994.

100. Stovner J, Oftedal N, Holmboe J: The inhibition of

cholinesterases by pancuronium. Br J Anaesth

47:949–954, 1975.

101. Bowman WC, Rodger IW, Houston J, et al:

Structure:action

relationships among some des-

acetoxy analogues of pancuronium and vecuro-

nium in the anesthetized cat. Anesthesiology

69:57–62, 1988.

102. Wierda JM, Proost JH: Structure-pharmacodyna-

mic-pharmacokinetic relationships of steroidal

neuromuscular blocking agents. Eur J Anaesthesiol

Suppl 11:45–54, 1995.

103. Naguib M, Samarkandi AH, Bakhamees HS, et

al: Comparative potency of steroidal neuromus-

cular blocking drugs and isobolographic analy-

sis of the interaction between rocuronium and

other aminosteroids. Br J Anaesth 75:37–42,

1995.

104. Goulden MR, Hunter JM: Rapacuronium (Org

9487): Do we have a replacement for succinylcho-

line? Br J Anaesth 82:489–492, 1999.

105. Boros EE, Samano V, Ray JA, et al: Neuromuscular

blocking activity and therapeutic potential of

mixed-tetrahydroisoquinolinium halofumarates and

halosuccinates in rhesus monkeys. J Med Chem

46:2502–2515, 2003.

106. Belmont MR, Lien CA, Tjan J, et al: Clinical phar-

macology of GW280430A in humans. Anesthesio-

logy 100:768–773, 2004.

107. Shanks CA: Pharmacokinetics of the nondepolari-

zing neuromuscular relaxants applied to calculation

of bolus and infusion dosage regimens.Anesthesio-

logy 64:72–86, 1986.

108. Booij LH, Knape HT: The neuromuscular blocking

effect of Org 9426. A new intermediately-acting

steroidal non-depolarising muscle relaxant in man.

Anaesthesia 46:341–343, 1991.

109. Bartkowski RR, Witkowski TA, Azad S, et al: Rocu-

ronium onset of action: A comparison with atracu-

rium and vecuronium. Anesth Analg 77:574–578,

1993.

110. Bevan DR, Fiset P, Balendran P, et al: Pharmacody-

namic behaviour of rocuronium in the elderly. Can

J Anaesth 40:127–132, 1993.

111. Savarese JJ, Lien CA, Belmont MR, Wastila WB:

[The clinical pharmacology of new benzylisoquino-

line-diester compounds, with special consideration

of cisatracurium and mivacurium.] Anaesthesist

46:840–849, 1997.

112. Naguib M, Samarkandi AH, Ammar A, et al: Com-

parative clinical pharmacology of rocuronium,

cisatracurium, and their combination. Anesthesio-

logy 89:1116–1124, 1998.

113. Weber S, Brandom BW, Powers DM, et al: Mivacu-

rium chloride (BWB1090U)-induced neuromuscu-

lar blockade during nitrous oxide–isoflurane and

nitrous oxide–narcotic anesthesia in adult surgical

patients. Anesth Analg 67:495–499, 1988.

114. Caldwell JE, Kitts JB, Heier T, et al: The dose-res-

ponse relationship of mivacurium chloride in

humans during nitrous oxide–fentanyl or nitrous

oxide–enflurane anesthesia. Anesthesiology 70:31–

35, 1989.

115. Diefenbach C, Mellinghoff H, Lynch J, Buzello W,

Mivacurium: Dose-response relationship and

administration by repeated injection or infusion.

Anesth Analg 74:420–423, 1992.

116. Wierda JM, Beaufort AM, Kleef UW, et al: Prelimi-

nary investigations of the clinical pharmacology of

three short-acting non-depolarizing neuromuscu-

lar blocking agents, Org 9453, Org 9489 and Org

9487. Can J Anaesth 41:213–220, 1994.

117. Kopman AF, Klewicka MM, Ghori K, et al: Dose-

response and onset/offset characteristics of

rapacuronium. Anesthesiology 93:1017–1021,

2000.

118. Kim KS, Chung CW, Shin WJ: Cisatracurium neu-

romuscular block at the adductor pollicis and the

laryngeal adductor muscles in humans.Br J Anaesth

83:483–484, 1999.

119. Holford NH, Sheiner LB: Understanding the dose-

effect rel

ationship:Clinical

application of pharmacoki-

netic-pharmacodynamic models. Clin Pharmacokinet

6:429–453, 1981.

120. Sheiner LB, Stanski DR,Vozeh S, et al: Simultaneous

modeling of pharmacokinetics and pharmacodyna-

mics: Application to

-tubocurarine. Clin Pharma-

col Ther 25:358–371, 1979.

121. Holford NH, Sheiner LB: Kinetics of pharmacologic

response. Pharmacol Ther 16:143–166, 1982.

122. Wright PM: Population based pharmacokinetic

analysis:Why

do we need it; what is it; and what has

it told us about anaesthetics? Br J Anaesth 80:488–

501, 1998.

123. Fisher DM, Rosen JI: A pharmacokinetic explana-

tion for increasing recovery time following larger or

repeated doses of nondepolarizing muscle relaxants.

Anesthesiology 65:286–291, 1986.

124. Bevan DR, Bevan JC, Donati F: Pharmacokinetic

principles. Muscle Relaxants in Clinical Anesthesia.

Chicago, Year Book, 1988.

125. Waser PG, Wiederkehr H, Sin-Ren AC, Kaiser-

Schonenberger E: Distribution and kinetics of

C-vecuronium in rats and mice. Br J Anaesth

59:1044–1051, 1987.

126. Matteo RS, Nishitateno K, Pua EK, Spector S: Phar-

macokinetics of

-tubocurarine in man: Effect of an

osmotic diuretic on urinary excretion. Anesthesio-

logy 52:335–338, 1980.

127. Lebrault C, Berger JL, D’Hollander AA, et al: Phar-

macokinetics and pharmacodynamics of vecuro-

nium (ORG NC 45) in patients with cirrhosis.

Anesthesiology 62:601–605, 1985.

128. Wood M: Plasma drug binding: Implications for

anesthesiologists. Anesth Analg 65:786–804, 1986.

129. McLeod K, Watson MJ, Rawlins MD: Pharmacoki-

netics of pancuronium in patients with normal and

impaired renal function. Br J Anaesth 48:341–345,

1976.

130. Miller RD, Matteo RS, Benet LZ, Sohn YJ: The phar-

macokinetics of

-tubocurarine in man with and

without renal failure. J Pharmacol Exp Ther 202:1–

7, 1977.

131. Wright PM, Hart P, Lau M, et al: Cumulative cha-

racteristics of atracurium and vecuronium. A

simultaneous clinical and pharmacokinetic study.

Anesthesiology 81:59–68, 1994.

132. Laurin J, Donati F, Nekka F,Varin F: Peripheral link

model as an alternative for pharmacokinetic-phar-

macodynamic modeling of drugs having a very

short elimination half-life. J Pharmacokinet

Biopharm 28:7–25, 2001.

133. Kuipers JA, Boer F, Olofsen E, et al: Recirculatory

pharmacokinetics and pharmacodynamics of rocu-

ronium in patients: The influence of cardiac output.

Anesthesiology 94:47–55, 2001.

134. Wright PM, Brown R, Lau M, Fisher DM: A phar-

macodynamic explanation for the rapid onset/offset

of rapacuronium bromide. Anesthesiology 90:16–

23, 1999.

135. Wierda JM, Meretoja OA, Taivainen T, Proost JH:

Pharmacokinetics and pharmacokinetic-dynamic

modelling of rocuronium in infants and children.

Br J Anaesth 78:690–695, 1997.

136. Bergeron L, Bevan DR, Berrill A, et al: Concentra-

tion-effect relationship of cisatracurium at three

different dose levels in the anesthetized patient.

Anesthesiology 95:314–323, 2001.

137. Fisher DM, Canfell PC, Spellman MJ, Miller RD:

Pharmacokinetics and pharmacodynamics of atra-

curium in infants and children. Anesthesiology

73:33–37, 1990.

138. Kitts JB, Fisher DM, Canfell PC, Sp, et al: Pharma-

cokinetics and pharmacodynamics of atracurium in

the elderly. Anesthesiology 72:272–275, 1990.

139. Parker CJ, Hunter JM: Dependence of the neuro-

muscular blocking effect of atracurium upon its

disposition. Br J Anaesth 68:555–561, 1992.

140. Marathe PH, Dwersteg JF, Pavlin EG, et al: Effect of

thermal injury on the pharmacokinetics and phar-

macodynamics of atracurium in humans. Anesthe-

siology 70:752–755, 1989.

141. Cronnelly R, Fisher DM, Miller RD, et al: Pharma-

cokinetics and pharmacodynamics of vecuronium

(ORG NC45) and pancuronium in anesthetized

humans. Anesthesiology 58:405–408, 1983.

142. Rupp SM, Castagnoli KP, Fisher DM, Miller RD:

Pancuronium and vecuronium pharmacokinetics

and pharmacodynamics in younger and elderly

adults. Anesthesiology 67:45–49, 1987.

143. Stanski DR, Ham J, Miller RD, Sheiner LB: Pharma-

cokinetics and pharmacodynamics of

-tubocura-

rine during nitrous oxide–narcotic and halothane

anesthesia in man. Anesthesiology 51:235–241,

1979.

144. Katz RL, Ryan JF: The neuromuscular effects of

suxamethonium in man. Br J Anaesth 41:381–390,

1969.

145. Kopman AF, Zhaku B, Lai KS: The“intubating dose”

of succinylcholine: The effect of decreasing doses

on recovery time. Anesthesiology 99:1050–1054,

2003.

146. Wierda JM, van den Broek L, Proost JH, et al: Time

course of action and endotracheal intubating con-

ditions of Org 9487, a new short-acting steroidal

muscle relaxant; a comparison with succinylcholine.

Anesth Analg 77:579–584, 1993.

147. Miguel R,Witkowski T, Nagashima H, et al: Evalua-

tion of neuromuscular and cardiovascular effects of

two doses of rapacuronium (ORG 9487) versus

mivacurium and succinylcholine. Anesthesiology

91:1648–1654, 1999.

148. Magorian T, Flannery KB, Miller RD: Comparison

of rocuronium, succinylcholine, and vecuronium

for rapid-sequence induction of anesthesia in adult

patients. Anesthesiology 79:913–918, 1993.

149. Naguib M: Neuromuscular effects of rocuronium

bromide and mivacurium chloride administered

alone and in combination. Anesthesiology 81:388–

395, 1994.

150. Agoston S, Salt P, Newton D, et al: The neuromus-

cular blocking action of ORG NC 45, a new pan-

curonium derivative, in anaesthetized patients. A

pilot study. Br J Anaesth 52(Suppl 1)53S–59S,

1980.

151. Miller RD, Agoston S, Booij LH, et al: The compa-

rative potency and pharmacokinetics of pancuro-

nium and its metabolites in anesthetized man. J

Pharmacol Exp Ther 207:539–543, 1978.

152. Savarese JJ, Ali HH, Antonio RP: The clinical phar-

macology of metocurine: Dimethyltubocurarine

revisited. Anesthesiology 47:277–284, 1977.

153. From RP, Pearson KS, Choi WW, et al: Neuromus-

cular and cardiovascular effects of mivacurium

chloride (BW B1090U) during nitrous oxide–

fentanyl–thiopentone and nitrous oxide–halothane

anaesthesia. Br J Anaesth 64:193–198, 1990.

154. Boyd AH, Eastwood NB, Parker CJ, Hunter JM:

Pharmacodynamics of the 1R cis-1

R cis isomer of

atracurium (51W89) in health and chronic renal

failure. Br J Anaesth 74:400–404, 1995.

Farmacología de los relajantes musculares y sus antagonistas

671

Sección II

Farmacología y anestesia